Cardiac toxicity risk factors identified with relapsed multiple myeloma therapy
More than half of patients with relapsed multiple myeloma treated with carfilzomib experienced cardiac issues during treatment, according to a multi-institutional study published June 12 in Journal of Clinical Oncology. The ...
Jun 13, 2019
0
0